ArticleThe International journal of eating disorders2026
Exploring Transdiagnostic Eating Disorder Symptoms and Disorder of Gut-Brain Interaction Symptoms in Individuals With Connective Tissue Disorders.
Article in The International journal of eating disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveIndividuals with connective tissue disorders (CTDs) commonly experience gastrointestinal (GI) symptoms resulting from disorders of gut-brain interaction (DGBI) and may attempt to manage GI distress with dietary restriction. Among adults with CTDs, we aimed to: (1) identify the prevalence and characteristics of avoidant/restrictive food intake disorder (ARFID) symptoms (ARFID+) and other eating disorder (e.g., anorexia nervosa, binge eating disorder, etc.) symptoms (Other-ED+), and (2) explore the relationship between GI symptom severity and ARFID+/Other-ED+.
methodParticipants (N = 205; ages 18-71 years; 94% female) completed surveys to assess ARFID+/Other-ED+, likely DGBI diagnoses, and GI symptom severity. We calculated the prevalence of ARFID+/Other-ED+ and likely DGBI and compared the demographics and symptom severity of those with vs. without ARFID+ or Other-ED+. We tested whether upper and/or lower GI symptom severity was associated with the presence of: (1) Other-ED+ or (2) ARFID+, controlling for age.
resultsLikely DGBI were common in CTDs (89%), as were Other-ED+ (50.2%) with lower frequency of ARFID+ (18%). While controlling for age, lower GI symptom severity was associated with odds of Other-ED+, but not ARFID+. DISCUSSION: Clinically significant Other-ED+ were 3× more prevalent than ARFID+ in adults with CTD, possibly driven by heightened lower GI symptom severity. Future research should clarify the temporality of Other-ED+ onset in the context of CTDs and relation to GI symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.